Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation

Acta Anaesthesiologica Scandinavica

Volumn 58, Issue 4, 2014, Pages 453-462

  Kottenberg, E ^a   Thielmann, M ^a   Kleinbongard, P ^a   Frey, U H ^a   Heine, T ^a   Jakob, H ^a   Heusch, G ^a   Peters, J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOFLURANE; PLACEBO; SULFONYLUREA; TROPONIN I;

AGED; ANESTHESIA INDUCTION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY SURGERY; DIABETES MELLITUS; DRUG EFFECT; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION PREVENTION; HUMAN; ISCHEMIC PRECONDITIONING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANESTHESIA, GENERAL; AREA UNDER CURVE; BLOOD GLUCOSE; COHORT STUDIES; CONSTRICTION; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MAMMARY ARTERIES; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL REVASCULARIZATION; RETROSPECTIVE STUDIES; SAPHENOUS VEIN; STERNOTOMY; SULFONYLUREA COMPOUNDS; TROPONIN I;

EID: 84896318610     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12278     Document Type: Article

References (38)

1. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, Mac Allister RJ, Yellon DM,. Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007; 370: 575-579.
2. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhäuser M, Peters J, Jakob H, Heusch G,. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass grafting with crystalloid cardioplegic arrest. Basic Res Cardiol 2010; 105: 657-664.
3. Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, Hoole SP,. Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up. Circ Cardiovasc Interv 2013; 6: 246-251.
4. Heusch G,. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013; 381: 166-175.
5. Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, Peters J,. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol-a clinical trial. Acta Anaesthesiol Scand 2011; 56: 30-38.
6. Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M,. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans. Circ Res 2012; 110: 111-115.
7. Kottenberg E, Musiolik J, Thielmann M, Jakob H, Peters J, Heusch G,. Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischemic preconditioning during coronary artery bypass grafting. J Thorac Cardiovasc Surg 2014; 147: 376-382.
8. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G,. Cardioprotection and improved prognosis by remote ischaemic preconditioning in a single-center randomized, double-blind controlled trial of coronary artery bypass surgery. Lancet 2013; 382: 597-604.
9. Heusch G, Boengler K, Schulz R,. Cardioprotection-nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118: 1915-1919.
10. Whittington HJ, Harding I, Stephenson CIM, Bell R, Hausenloy DJ, Mocanu MM, Yellon DM,. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res 2013; 99: 694-704.
11. Przyklenk K,. Efficacy of cardioprotective conditioning strategies in aging and diabetic cohorts. Drugs Aging 2011; 28: 331-343.
12. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC,. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000; 278: H1218-1224.
13. Tanaka K, Kehl F, Gu W,. Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 2002; 282: H2018-2023.
14. Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, Warltier DC,. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 2001; 280: H1744-1750.
15. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM,. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005; 54: 2360-2364.
16. Meier JJ, Gallwitz B, Schmidt WE, Mügge A, Nauck MA,. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9-12.
17. Gross G, Auchampach JA,. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
18. Schulz R, Rose J, Heusch G,. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994; 267: H1341-1352.
19. Schulz R, Post H, Sakka S, Wallbridge DR, Heusch G,. Intraischemic preconditioning: increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia without intermittent reperfusion. Circ Res 1995; 76: 942-950.
20. Schulz R, Gres P, Heusch G,. Activation of ATP-dependent potassium channels is a trigger but not a mediator of ischaemic preconditioning in pigs. Br J Pharmacol 2003; 139: 65-72.
21. Kersten JR, Lowe D, Hettrick DA, Pagel PS, Gross GJ, Warltier DC,. Glyburide, a KATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium. Anesth Analg 1996; 83: 27-33.
22. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA,. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999; 67: 1045-1052.
23. Kleinbongard P, Thielmann M, Jakob H, Peters J, Heusch G, Kottenberg E,. Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia. Cardiovasc Drugs Ther 2013; 27: 359-361.
24. Sack MN, Yellon DM,. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003; 41: 1404-1407.
25. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM,. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008; 103: 274-284.
26. Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM,. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 2013; 27: 5-16.
27. Groop L,. Sulfonylurea in NIDDM. Diabetes Care 1992; 15: 737-754.
28. Liu Y, Sato T, O'Rourke B, Marban E,. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998; 97: 2463-2469.
29. ATP channels triggers the preconditioned state by generating free radicals. Circ Res 2000; 87: 460-466.
30. Heinzel FR, Luo Y, Li X, Boengler K, Buechert A, Garcia-Dorado D, Di Lisa F, Schulz R, Heusch G,. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexion 43 deficient mice. Circ Res 2005; 97: 583-586.
31. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, Gruber D, Harris S, Burger W,. Sulfonylureas and ischaemic preconditioning; a double blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446.
32. Cleveland JC, Meldrun DR, Cain BS, Banerjee A, Harken AH,. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 1997; 96: 29-32.
33. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr., Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.
34. ATP channels. Br J Pharmacol 2001; 133: 193-199.
35. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM,. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111-3116.
36. Hausenloy DJ, Wynne AM, Mocanu MM, Yellon DM,. Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. J Cardiovasc Pharmacol Ther 2012; 18: 263-269.
37. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L,. Derivation and prospective validation of a simple index for prediction of cardiac risk for major noncardiac surgery. Circulation 1999; 100: 1043-1049.
38. Szabo Z, Hakanson E, Svedjeholm R,. Early postoperative outcome and medium-term survival in 540 diabetics and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2002; 74: 712-719.